Novozymes Half-Life Extension Technology Embraced by Paras Biopharmaceuticals to Develop New Biobetter
Novozymes Biopharma and Paras Biopharmaceuticals will collaborate to generate an improved version (a biobetter) of Teriparatide, a leading treatment for osteoporosis, a debilitating bone disease largely affecting women over 50 years of age.
“The collective strengths of Paras Biopharmaceuticals’ and Novozymes’ technical expertise will bring solutions and treatment options to help osteoporosis patients”, says Dr. Hans Söderlund, Director of Global Strategic Alliance at Paras Biopharmaceuticals Finland Oy. “Novozymes’ VELTIS technology and Paras Biopharmaceuticals’ Diabrid NobleCleav technology will create a superior osteoporosis medicine”, added Dr. Ashesh Kumar, Director of Biologics and Licensing at Paras Biopharmaceuticals Finland Oy.
Already well-established in the fields of diabetes, hemophilia, and neutropenia, the VELTIS platform provides once-weekly, once bi-weekly or once-monthly peptide or protein dosing. As a result, VELTIS offers the potential for enhanced patient adherence and improved therapeutic impact.
“This is further market validation of the Novozymes Biopharma’s VELTIS technology,” says Svend Licht, Director at Novozymes Biopharma. “The versatile capabilities of our solution are being continually demonstrated by our customers. We are happy to enable the development of this biobetter, in addition to running numerous collaborations in life cycle management and new drug candidates.”
The agreement is not expected to impact Novozymes’ financial expectations for 2015.
Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet’s resources and helping build better lives. As the world’s largest provider of enzyme and microbial technologies, its bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that people rely on today and in the future. For more information, visit www.novozymes.com.
Based in Oulu, Finland, Paras Biopharmaceuticals is an award winning, privately held Finnish company focused on developing biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. The company’s facilities (European GMP US-FDA compliant) in Finland are dedicated to the development, scale-up, and GMP production of recombinant products for osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes), and oncology, in addition to high-value recombinant enzymes, such as Enterokinase (and other enzymes in pipeline). Paras Biopharmaceuticals has successfully developed its Diabrid Technology Platform (Diabrid Technology, NobleCleav Technolgy, and Biomultifold Microbial High Expression Technolgy) for the high level expression of biosimilars in specially designed genetically stable clones.
For more information, visit www.parasbiopharma.com.
Total Page Views: 971
